These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32244744)

  • 1. Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.
    Dhuguru J; Skouta R
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32244744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
    Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
    Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer.
    Kaur K; Jaitak V
    Anticancer Agents Med Chem; 2019; 19(8):962-983. PubMed ID: 30864529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indole: A privileged scaffold for the design of anti-cancer agents.
    Wan Y; Li Y; Yan C; Yan M; Tang Z
    Eur J Med Chem; 2019 Dec; 183():111691. PubMed ID: 31536895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.
    Salerno S; Barresi E; Baglini E; Poggetti V; Da Settimo F; Taliani S
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
    Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors.
    Chen Y; Zhang L; Zhang L; Jiang Q; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):425-436. PubMed ID: 33445997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
    Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
    Seo SY
    Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
    Chang SM; Christian W; Wu MH; Chen TL; Lin YW; Suen CS; Pidugu HB; Detroja D; Shah A; Hwang MJ; Su TL; Lee TC
    Eur J Med Chem; 2017 Feb; 127():235-249. PubMed ID: 28064078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach.
    Devi N; Kaur K; Biharee A; Jaitak V
    Anticancer Agents Med Chem; 2021; 21(14):1802-1824. PubMed ID: 33397272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Developments in the Synthesis and Anticancer Activity of Indole and Its Derivatives.
    Kaur B; Venugopal S; Verma A; Sahu SK; Wadhwa P; Kumar D; Sharma A
    Curr Org Synth; 2023; 20(4):376-394. PubMed ID: 35538803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
    Kharb R
    Anticancer Agents Med Chem; 2021; 21(11):1338-1349. PubMed ID: 32560614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
    Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
    Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.
    Panathur N; Dalimba U; Koushik PV; Alvala M; Yogeeswari P; Sriram D; Kumar V
    Eur J Med Chem; 2013 Nov; 69():125-38. PubMed ID: 24013412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.